What is the AI rating for MRK?

Merck & Co., Inc. (MRK) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are the key strengths of MRK?

Outstanding profitability with 28.1% net margin and 32.4% operating margin, demonstrating pricing power and operational efficiency. Exceptional return on equity of 34.7% indicates superior capital deployment and shareholder value creation. Strong free cash flow generation of $12.4B with 19% FCF margin provides resources for R&D, dividends, and debt service

What are the risks of investing in MRK?

Anemic revenue growth of 1.3% YoY reflects patent cliff pressures and competitive generic/biosimilar threats typical in mature pharma. Net income growth stalled at 0.0% YoY despite revenue growth, signaling margin pressure or restructuring costs. Elevated long-term debt of $46.8B creates refinancing risk in rising interest rate environment despite strong coverage ratios

MRK Stock Analysis - Merck & Co., Inc. AI Rating & Fundamentals

Name: Merck & Co., Inc. (MRK) Stock
Brand: Merck & Co., Inc.
Rating: 4 (1 reviews)

Investment Thesis

Merck demonstrates exceptional financial health with industry-leading profitability metrics (28.1% net margin, 34.7% ROE) and robust cash generation ($12.4B FCF). Strong interest coverage (69.5x) and solid liquidity position (1.54x current ratio) provide financial flexibility, though revenue growth remains modest at 1.3% YoY, reflecting mature market pressures typical in pharmaceuticals.

MRK Strengths

+ Outstanding profitability with 28.1% net margin and 32.4% operating margin, demonstrating pricing power and operational efficiency
+ Exceptional return on equity of 34.7% indicates superior capital deployment and shareholder value creation
+ Strong free cash flow generation of $12.4B with 19% FCF margin provides resources for R&D, dividends, and debt service
+ Fortress balance sheet with minimal leverage (0.89x debt/equity) and exceptional interest coverage (69.5x) providing financial stability
+ Solid liquidity position (1.54x current ratio, 1.30x quick ratio) ensures operational flexibility

MRK Risks

! Anemic revenue growth of 1.3% YoY reflects patent cliff pressures and competitive generic/biosimilar threats typical in mature pharma
! Net income growth stalled at 0.0% YoY despite revenue growth, signaling margin pressure or restructuring costs
! Elevated long-term debt of $46.8B creates refinancing risk in rising interest rate environment despite strong coverage ratios
! Patent expirations on key products pose ongoing revenue risks requiring successful new drug pipeline commercialization

Key Metrics to Watch

* Revenue growth trajectory - critical to assess whether pipeline innovations can offset patent cliff erosion
* Free cash flow sustainability - monitor if $12.4B FCF can be maintained amid slowing revenue growth
* Operating margin trends - track whether cost management can offset pricing pressures and competitive dynamics
* Debt reduction progress - watch debt/equity ratio movements given $46.8B long-term debt burden

MRK Financial Metrics

Revenue

$65.0B

Net Income

$18.3B

EPS (Diluted)

$7.28

Free Cash Flow

$12.4B

Total Assets

$136.9B

Cash Position

$14.6B

MRK Profitability Ratios

Gross Margin N/A

Operating Margin 32.4%

Net Margin 28.1%

ROE 34.7%

ROA 13.3%

FCF Margin 19.0%

MRK Balance Sheet & Liquidity

Current Ratio

1.54x

Quick Ratio

1.30x

Debt/Equity

0.89x

Debt/Assets

0.0%

Interest Coverage

69.53x

Long-term Debt

$46.8B

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

Data Source: SEC EDGAR | Analysis Date: Mar 18, 2026 | Data as of: 2025-12-31 | Powered by Claude AI